US 10610563
Use of ubiquitin-proteasome system inhibitors for treatment of tumors associated with neurofibromatosis type-2
granted A61KA61K31/39A61K31/573
Quick answer
US patent 10610563 (Use of ubiquitin-proteasome system inhibitors for treatment of tumors associated with neurofibromatosis type-2) held by BIOXCEL CORPORATION expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- BIOXCEL CORPORATION
- Grant date
- Tue Apr 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 25
- CPC classes
- A61K, A61K31/39, A61K31/573, A61K31/69, A61K38/05